Use of Objective Electrophysiology Findings to Reduce Trial and Error Pharmacotherapy and its Potential to Reduce Patient Suicidality

Des Moines, IA US
September 26, 2018

Registration


This presentation is a part of the "Do No Harm" series. All interested healthcare providers are weclome to attend. Registration is not required. 

Other "Do No Harm" Events

Purpose

Last year, Facebook announced that its artificial intelligence algorithms can now predict suicide, based purely on your social media footprint (1,2). Unfortunately, only half of patients with a mental disorder will ever seek mental healthcare, half will dropout of care, and less than half will respond to the treatments they are prescribed (3). Facing a 30% growth in suicide in the US (4), we need a better way to target treatments and maintain adherence to treatments that work. Physicians are now turning to some of the same artificial intelligence tools that classify population subgroups for advertising, shopping, or dating — to match patients to individualized pharmacotherapy, with promising clinical evidence.(5)  

Led by two accomplished physicians and military leaders, this program will summarize the latest developments in the use of electrophysiology and machine learning to diagnose psychiatric disorders, to predict treatment outcomes, and even to reduce suicidal thinking.  Drs Schneider and Xenakis will review the evolution of clinical biomarkers in Psychiatry, the latest research on depression treatment failure and its relationship to Suicidality, and the response of physicians to “crowdsource” biomarkers for more effective, targeted treatments. They will discuss case and institutional examples of the latest applications for targeting treatment in Psychiatry, as well as research on the measurement and prevention of suicidal ideation in clinical practice.

Learning Objectives

  • Review evolution of clinical biomarkers in psychiatry — for both clinical diagnosis and treatment selection 
  • Discuss current research on suicidality and its relationship to trial and order treatment modalities
  • Evaluate current sources of objective data to guide treatment
  • Review current evidence for and research for biomarker-guided treatment in Psychiatry
  • Review case studies and institutional examples

Faculty

Colonel Brett Schneider, MD recently retired from the US Army and is now Associate Clinical Professor of Psychiatry at Uniformed Services University.  An Iowa native, Dr. Schneider was deployed twice in Iraq, was the inaugural Chief of the Department of Psychiatry at Walter Reed National Military Medical Center, and was the DOD Champion for the VA/DOD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide. 

Stephen Xenakis, MD is a retired brigadier general and Army medical corps officer with 28 years of active service. Dr. Xenakis is board certified by the American Board of Psychiatry and Neurology in General Psychiatry, is an adjunct clinical professor at the Uniformed Services University of Health Sciences, and Founder of the Center for Translational Medicine. He has been a senior adviser to the Department of Defense on neurobehavioral conditions and medical management, and an anti-torture advisor to Physicians for Human Rights.  

Disclosures

The following speakers and planning committee members have no conflicts with commercial interest companies to disclose.

  • Sue Huppert, Planning Committee
  • Lisa Streyffeler, PhD, Planning Committee

The following speakers and planning committee members have a conflict(s) with commercial interest companies to disclose.

  • George Carpenter - Planning Committee, Employee of Mynd Analytics
  • Colonel Brett Schneider, MD (Retired) - Speaker, Honoraria from Mynd Analytics
  • Brigadier General Stephen Xenakis, MD (Retired) - Speaker, Consultant and self-managed stock holder for Mynd Analytics

References

  1. Wired, Artificial Intelligence is Learning to Predict and Prevent Suicide, 3/17/17
  2. Facebook, Under the hood: Suicide prevention tools powered by AI, posted 2/21/18
  3. Tylee and Jones, Managing depression in primary care, BMJ. 2005 Apr 9; 330(7495): 800–801, doi: 10.1136/bmj.330.7495.800
  4. Centers for Disease Control and Prevention, 9-21-18
  5. Carpenter et. al., A Promising New Strategy to Improve Treatment Outcomes for Patients with Depression, Population Health Management, 2018  DOI: 10.1089/pop.2018.0101

Course summary
Available credit: 
  • 1.00 AOA Category 2­A
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 IBON
  • 1.00 CE Contact Hours
Course opens: 
09/26/2018
Course expires: 
09/26/2018
Event starts: 
09/26/2018 - 5:00pm
Event ends: 
09/26/2018 - 6:00pm
Cost:
$0.00
Des Moines University
3200 Grand Avenue
SEC Auditorium
Des Moines, IA 50312
United States
+1 (515) 271-1596

Des Moines University is located on a 22-acre campus in the heart of Des Moines, Iowa. Just west of downtown on Grand Avenue, the University is located in one of Des Moines' most prestigious neighborhoods. The campus is in a historic neighborhood filled with tree-lined streets and gracious older homes and businesses. Its central location makes it easy to access the rest of the city and outlying communities. The campus is close to the Des Moines International Airport, located on the bus line and just blocks from local shopping and downtown Des Moines.

Travel

Continuing Education Credit

  • MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
  • Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
  • Other healthcare providers: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.

Educational Grants

No commercial interest company provided financial support for this continuing education activity. 

Disclosure

Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.

Available Credit

  • 1.00 AOA Category 2­A
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 IBON
  • 1.00 CE Contact Hours

Accreditation Period

Course opens: 
09/26/2018
Course expires: 
09/26/2018

Price

Cost:
$0.00
Please login or Create an Account to take this course.